ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 135 filers reported holding ROYALTY PHARMA PLC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $129,255 | -16.0% | 4,762 | -5.1% | 0.00% | – |
| Q2 2023 | $153,897 | -16.0% | 5,019 | -1.3% | 0.00% | – |
| Q1 2023 | $183,285 | +10.8% | 5,083 | +21.6% | 0.00% | – |
| Q4 2022 | $165,435 | -5.5% | 4,179 | -3.8% | 0.00% | – |
| Q3 2022 | $175,000 | -10.3% | 4,344 | -6.4% | 0.00% | – |
| Q2 2022 | $195,000 | +29.1% | 4,642 | +8.8% | 0.00% | – |
| Q1 2022 | $151,000 | -2.6% | 4,265 | +9.4% | 0.00% | – |
| Q4 2021 | $155,000 | +34.8% | 3,899 | +22.5% | 0.00% | – |
| Q3 2021 | $115,000 | -59.1% | 3,183 | -53.6% | 0.00% | -100.0% |
| Q2 2021 | $281,000 | -56.6% | 6,861 | -53.8% | 0.00% | -50.0% |
| Q1 2021 | $648,000 | -22.6% | 14,866 | -11.1% | 0.00% | 0.0% |
| Q4 2020 | $837,000 | +11.0% | 16,721 | -6.8% | 0.00% | 0.0% |
| Q3 2020 | $754,000 | +216.8% | 17,942 | +267.2% | 0.00% | +100.0% |
| Q2 2020 | $238,000 | – | 4,886 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |